HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
Joint Authors
Bacigalupo, Andrea
Sica, Simona
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-04-07
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants.
PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders.
Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome.
The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.
American Psychological Association (APA)
Bacigalupo, Andrea& Sica, Simona. 2016. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Advances in Hematology،Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1095110
Modern Language Association (MLA)
Bacigalupo, Andrea& Sica, Simona. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Advances in Hematology No. 2016 (2016), pp.1-5.
https://search.emarefa.net/detail/BIM-1095110
American Medical Association (AMA)
Bacigalupo, Andrea& Sica, Simona. HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide. Advances in Hematology. 2016. Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1095110
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1095110